6-chloro-4-methyl-1H-indazole | 885520-87-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 6-chloro-4-methyl-1H-indazole
• CAS: 885520-87-6
• 化学式: C₈H₇ClN₂
• mdl: MFCD07781472
• 分子量: 166.61
• InChiKey: JDLULNKWAGWMEO-UHFFFAOYSA-N

物化性质

• 沸点：
  326.1±22.0 °C(Predicted)
• 密度：
  1.351±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE
  申请人：Lycera Corporation

  公开号：US20150119439A1

  公开（公告）日：2015-04-30

  The invention provides saturated acyl guanidine compounds that inhibit F 1 F 0 -ATPase, and methods of using saturated acyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

  该发明提供了饱和脂肪酰基胍化合物，可以抑制F1F0-ATP酶，并且使用饱和脂肪酰基胍化合物作为治疗剂治疗医疗障碍的方法，例如免疫障碍、炎症状况或癌症。
• INDAZOLE GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF
  申请人：Lycera Corporation

  公开号：US20150152063A1

  公开（公告）日：2015-06-04

  The invention provides indazole guanidine compounds that inhibit F 1 F 0 -ATPase, and methods of using indazole guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

  该发明提供了一种抑制F1F0-ATP酶的吲唑胍化合物，并使用吲唑胍化合物作为治疗剂治疗医学疾病，例如免疫紊乱、炎症病症或癌症的方法。
• Novel Compounds
  申请人：Glaxo Group Limited

  公开号：US20150328226A1

  公开（公告）日：2015-11-19

  The invention provides a combination comprising compounds of formula (I) or salts thereof, and one or more therapeutic agents.

  本发明提供了一种组合物，包括式(I)化合物或其盐，以及一种或多种治疗剂。
• PYRIMIDINONES AS FACTOR XIA INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160096839A1

  公开（公告）日：2016-04-07

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了以下化合物（I）或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量均如本文所定义。这些化合物是选择性因子XIa抑制剂或FXIa和血浆卡利肽酶双重抑制剂。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗血栓栓塞性和/或炎症性疾病的方法。
• MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20170002006A1

  公开（公告）日：2017-01-05

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.